Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Anatara Lifesciences Ltd ( (AU:ANR) ) is now available.
Anatara Lifesciences Ltd announced a change in the director’s interest, with Dr. David Brookes acquiring additional shares through entities Tarandi and Dahlbrook Family Trust. This acquisition, valued at $40,000, reflects a strategic move that could influence the company’s market positioning and stakeholder confidence.
More about Anatara Lifesciences Ltd
Anatara Lifesciences Ltd operates in the biotechnology industry, focusing on developing therapeutic solutions for gastrointestinal diseases. The company is known for its innovative approach to addressing unmet medical needs in both human and animal health markets.
Average Trading Volume: 3,342,970
Technical Sentiment Signal: Sell
Current Market Cap: A$2.97M
For a thorough assessment of ANR stock, go to TipRanks’ Stock Analysis page.